51.77 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||51.72 x 900|
|Ask||51.73 x 900|
|Day's range||51.68 - 52.20|
|52-week range||42.80 - 55.00|
|Beta (5Y monthly)||0.39|
|PE ratio (TTM)||8.87|
|Forward dividend & yield||1.91 (3.78%)|
|Ex-dividend date||03 May 2021|
|1y target est||63.88|
Yahoo Finance’s Anjalee Khemlani reports the latest updates on the coronavirus.
Dr. Brittani James, Co-Founder of The Institute for Antiracism in Medicine & Assistant Professor of Clinical Family Medicine at The University of Illinois College of Medicine, joins Yahoo Finance Live to discuss the latest on the coronavirus pandemic.
The French-based pharmaceutical company Sanofi (NASDAQ: SNY) has been flying under the radar over the past few years as companies like AbbVie, Bristol Myers Squibb, and Merck have dominated the space through the tremendous success of their drugs. Sanofi was actually a creation of several different companies, including Aventis, Synthélabo, Hoechst, Rhône-Poulenc Rorer, and several others. Through mergers and acquisitions (M&A) we got the Sanofi we know today.